Home > Insider Trading > Filing (0001209191-15-049860)

Filing Details

Accession Number:: 0001209191-15-049860
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2015-06-03 19:40:01
Reporting Period:: 2015-06-01

Filing Date:: 2015-06-03
Accepted Time:: 2015-06-03 19:40:01
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1510580	Kite Pharma Inc.	KITE	Biological Products, (No Disgnostic Substances) (2836)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1609805	Ran Nussbaum	C/O Kite Pharma, Inc. 2225 Colorado Avenue Santa Monica CA 90404		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2015-06-01	69,206	$55.05	236,228	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2015-06-01	3,754	$56.44	232,474	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2015-06-01	7,800	$57.38	224,674	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2015-06-02	200,604	$55.27	24,070	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2015-06-02	24,070	$56.08	0	No	4	S	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote

Footnotes

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2015.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55 to $56, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
The shares of common stock are held in the name of Pontifax (Israel) II, L.P., Pontifax (Cayman) II, L.P., and Pontifax (Israel) II - Individual Investors L.P. The reporting person is a director of Pontifax Management 2 G.P. (2007) Ltd., the general partner of Pontifax (Cayman) II, L.P., Pontifax (Israel) II, L.P. and Pontifax (Israel) II - Individual Investors L.P.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.01 to $57.01, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.02 to $57.88, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
Following the sale of shares of common stock in a series of block trades on June 1, 2015, 82,911 shares of common stock were held in the name of Pontifax (Israel) II, L.P., 109,688 shares of common stock were held in the name of Pontifax (Cayman) II, L.P., and 32,075 shares of common stock were held in the name of Pontifax (Israel) II - Individual Investors L.P.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55 to $55.985, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56 to $56.22, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.